ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO536

The Bioimpedance Spectroscopy to Preserve Renal Output (BISTRO) Multicentre Randomised Controlled Trial: Quality of Life and Blood Pressure Outcomes

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Davies, Simon J., Keele University, Keele, Staffordshire, United Kingdom
  • Zanganeh, Mandana, University of Warwick University House, Coventry, West Midlands, United Kingdom
  • Solis-Trapala, Ivonne, Keele University, Keele, Staffordshire, United Kingdom
  • Keane, David Francis, Leeds Teaching Hospitals NHS Trust, Leeds, Leeds, United Kingdom
  • Davenport, Andrew, Royal Free London NHS Foundation Trust, London, London, United Kingdom
  • Wilkie, Martin E., Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Sheffield, United Kingdom
  • Ormandy, Paula, University of Salford, Salford, Greater Manchester, United Kingdom
  • Macdonald, Jamie Hugo, Bangor University, Bangor, Gwynedd, United Kingdom
  • Dasgupta, Indranil, NHS Birmingham and Solihull Clinical Commissioning Group, Birmingham, Birmingham, United Kingdom
  • Farrington, Ken, Hertfordshire Partnership University NHS Foundation Trust, Hatfield, Hertfordshire, United Kingdom
  • Caskey, Fergus, University of Bristol, Bristol, Bristol, United Kingdom

Group or Team Name

  • on behalf of the BISTRO Investigators

BISTRO examined if using bioimpedance (BIS) to avoid setting the post-dialysis target weight (PD-TW) below the normally hydrated weight (NHW) could preserve residual kidney function (RKF) when compared to a standardized fluid management protocol. This pre-specified secondary analysis reports the effect of BIS on health-related quality of life, symptoms, and blood pressure.


BISTRO is an open-label, clinician-blinded, randomized controlled trial in incident HD patients with >500ml urine volume/day or residual GFR >3 ml/min/m2. Randomization was by centralized concealed allocation, 1:1, stratified by centre. BIS measurements were taken by independent observers and concealed in the control arm. Secondary outcomes included BP, self-rated health (EQ visual analogue scale), dialysis symptoms, health-related quality of life (EuroQol and Short Form 12), collected at baseline and 3-monthly until month 24. ISCCTN Number: 11342007; Funding: UK NIHR Health Technology Assessment Programme


Questionnaire completeness was 52%–89%, similar by group. Median EQ-VAS rose from 60 to 65 in both groups at 3 months, then back to baseline, remaining stable. Despite a progressive fall in RKF, dialysis symptoms were remarkably stable over 24 months (see Table) with only modest worsening of recovery time, no between-group differences. There was no longitudinal change or between-group difference in BP, just a tendency for a lower post-dialytic BP and more hypotensive symptoms in the control group between 18 and 24 months. Mean difference in PD-TW and NHW was not different between study arm assessments: BIS, n=1335 observations, –0.038Kg (SD 2.7); Control, n=1166 –0.25Kg (2.6)


Using a standardised fluid assessment protocol secondary outcomes were stable in those remaining in the trial and not benefited by the addition of BIS, possibly because clinician fluid assessments were close to the NHW.


  • Government Support – Non-U.S.